BACKGROUND: Claudins are a family of approximately 23 integral membrane tight junction (TJ) proteins that maintain cell polarity and paracellular barrier functions in epithelial and endothelial cells. Although Claudin-1 was demonstrated to be typically downregulated in various cancers, the precise expression patterns of this protein in normal and neoplastic tissues remain poorly characterized. METHODS: Using immunohistochemistry, the expression of Claudin-1 was investigated in prostate tissue samples arranged in a tissue microarray (TMA) format and comprising elements of normal prostatic epithelium (n = 6), benign prostatic hyperplasia (BPH; n = 38), prostatic intraepithelial neoplasia (PIN; n = 11), and prostate adenocarcinoma (n = 48). The Claudin-1 expression pattern was compared with that of the basal cell-specific markers, p63, and HMW cytokeratin (34betaE12), by employing double-labeling techniques in conjunction with image analysis methods utilizing color deconvolution algorithms. RESULTS: In benign prostatic epithelium, pronounced Claudin-1 expression was observed in the basal cell layer with no staining in luminal cells. Prostate adenocarcinoma specimens from 98% (47/48) patients lacked Claudin-1 immunostaining, and no cases contained >5% immunopositive tumor cells. CONCLUSIONS: Claudin-1 immunohistochemistry should be considered for use as a new diagnostic tool for distinguishing malignant from benign lesions of the prostate.
BACKGROUND: Claudins are a family of approximately 23 integral membrane tight junction (TJ) proteins that maintain cell polarity and paracellular barrier functions in epithelial and endothelial cells. Although Claudin-1 was demonstrated to be typically downregulated in various cancers, the precise expression patterns of this protein in normal and neoplastic tissues remain poorly characterized. METHODS: Using immunohistochemistry, the expression of Claudin-1 was investigated in prostate tissue samples arranged in a tissue microarray (TMA) format and comprising elements of normal prostatic epithelium (n = 6), benign prostatic hyperplasia (BPH; n = 38), prostatic intraepithelial neoplasia (PIN; n = 11), and prostate adenocarcinoma (n = 48). The Claudin-1 expression pattern was compared with that of the basal cell-specific markers, p63, and HMW cytokeratin (34betaE12), by employing double-labeling techniques in conjunction with image analysis methods utilizing color deconvolution algorithms. RESULTS: In benign prostatic epithelium, pronounced Claudin-1 expression was observed in the basal cell layer with no staining in luminal cells. Prostate adenocarcinoma specimens from 98% (47/48) patients lacked Claudin-1 immunostaining, and no cases contained >5% immunopositive tumor cells. CONCLUSIONS:Claudin-1 immunohistochemistry should be considered for use as a new diagnostic tool for distinguishing malignant from benign lesions of the prostate.
Authors: Eszter Székely; Péter Törzsök; Péter Riesz; Anna Korompay; Attila Fintha; Tamás Székely; Gábor Lotz; Péter Nyirády; Imre Romics; József Tímár; Zsuzsa Schaff; András Kiss Journal: J Histochem Cytochem Date: 2011-08-10 Impact factor: 2.479
Authors: A M Szasz; A M Tokes; M Micsinai; T Krenacs; Cs Jakab; L Lukacs; Zs Nemeth; Zs Baranyai; K Dede; L Madaras; J Kulka Journal: Clin Exp Metastasis Date: 2010-10-21 Impact factor: 5.150
Authors: Laura E Pascal; Rajiv Dhir; Goundappa K Balasubramani; Wei Chen; Chandler N Hudson; Pooja Srivastava; Anthony Green; Donald B DeFranco; Naoki Yoshimura; Zhou Wang Journal: Am J Clin Exp Urol Date: 2021-02-15
Authors: Maryla Krajewska; Layton H Smith; Juan Rong; Xianshu Huang; Marc L Hyer; Nikolajs Zeps; Barry Iacopetta; Steven P Linke; Allen H Olson; John C Reed; Stan Krajewski Journal: J Histochem Cytochem Date: 2009-03-16 Impact factor: 2.479
Authors: Maryla Krajewska; Shinichi Kitada; Jane N Winter; Daina Variakojis; Alan Lichtenstein; Dayong Zhai; Michael Cuddy; Xianshu Huang; Frederic Luciano; Cheryl H Baker; Hoguen Kim; Eunah Shin; Susan Kennedy; Allen H Olson; Andrzej Badzio; Jacek Jassem; Ivo Meinhold-Heerlein; Michael J Duffy; Aaron D Schimmer; Ming Tsao; Ewan Brown; Anne Sawyers; Michael Andreeff; Dan Mercola; Stan Krajewski; John C Reed Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Dmitri V Rozanov; Alexei Y Savinov; Roy Williams; Kang Liu; Vladislav S Golubkov; Stan Krajewski; Alex Y Strongin Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Feng Li; Laura E Pascal; Ke Wang; Yibin Zhou; Goundappa K Balasubramani; Katherine J O'Malley; Rajiv Dhir; Kai He; Donna Stolz; Donald B DeFranco; Naoki Yoshimura; Joel B Nelson; Tie Chong; Peng Guo; Dalin He; Zhou Wang Journal: Am J Clin Exp Urol Date: 2020-02-25
Authors: Sandeep K Nadendla; Allon Hazan; Matt Ward; Lisa J Harper; Karwan Moutasim; Lucia S Bianchi; Mahmoud Naase; Lucy Ghali; Gareth J Thomas; David M Prowse; Michael P Philpott; Graham W Neill Journal: PLoS One Date: 2011-05-25 Impact factor: 3.240
Authors: Yuan Tian; Caitlin H Choi; Qing Kay Li; Farah B Rahmatpanah; Xin Chen; Sara Ruth Kim; Robert Veltri; David Chia; Zhen Zhang; Dan Mercola; Hui Zhang Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240